Saniona currently has clinical stage candidates for obesity, metabolic diseases and cocaine addiction and has been able to secure collaborations with top pharmaceutical companies.
Saniona has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix, S.A and Luc Therapeutics, Inc.
Tesomet and Tesofensine are the most advanced programs.
Pipeline Product to target - Indication - Market - Status
Tesomet has recently shown positive results in its Phase2a study for type 2 diabetes and the Company is currently conducting a Phase 2a study in patients suffering from Prader-Willi syndrome. Acc. to Datamonitor, it is expected that the type 2 diabetes market will grow from $23.3bn in 2014 to $43bn in 2023.
Tesomet - Type 2 diabetes - 23 billion USD (Clinical phase 2)
Tesomet PWS - Prader-Willi syndrome - 2 billion USD only in USA (Clinical phase 2)
Tesofensine - Obesity - 250 million USD only in Mexiko (Clinical phase 3)
NS2359 - Cocaine addiction - 1,8 billion USD only in USA (Clinical phase 2)
GABA-A α2/α3 program - Neuropathic pain - 6 billion USD (Preclinical research)
Boehringer Ingelheim program - Schizophrenia - 4,8 billion USD (Preclinical research)
IK - Inflammation, IBD - 5,9 billion USD (Preclinical research)
Nicotinic α6 program - Parkinson - 2,8 billion USD (Preclinical research)
Proximagen program - Neurological disorders - No data (Preclinical research)
Luc Therapeutic program - Ataxia - Rare disease (Preclinical research
Current market cap approximately 125 million USD
List of Major Shareholders
Jørgen Drejer 11.4% CEO and founder of Saniona
Thomas Feldthus 9% EVP, CFO and Co-founder
Avanza Pension 5.9%
Leif Andersson 4.6% Board member
Palle Christophersen 3.9% CSO and Co-founder
Claus Brästrup 3.5% Chairman
Nordnet Pensionsförsäkring 3.1%
Janus Schreiber Larsen 2.1% Project Director and Co-founder
Jörgen Philip Kiär Ahring 1.9%
Karin Sandager Nielsen 1.7% Head of in vivo pharmacology